Multi-ancestry genetic score improves risk prediction for Alzheimer’s disease
Late-onset Alzheimer disease (AD) is a progressive disorder characterized by cognitive decline and memory impairment, affecting an estimated…
Revolution Medicines gets FDA nod for targeted pancreatic cancer drug
Menta “Steve” Wallace shows a bottle of daraxonrasib, Revolution Medicines’ pancreatic cancer drug, at his home in The…
How AI is changing the pharmaceuticals landscape
Nintedanib, a widely used drug for pulmonary fibrosis, received official approval in 2014 after its development began in…
Laser treatment may extend survival in glioblastoma patients
For patients facing a diagnosis of glioblastoma – one of the most aggressive and devastating forms of brain…
Novo Nordisk CEO defends lawsuit against Eli Lilly: ‘Competition has to be fair’
Novo Nordisk CEO Mike Doustdar on Wednesday defended the drugmaker’s decision to sue rival Eli Lilly over its…
Lilly sues six firms over alleged illegal sales of obesity drug retatrutide
Eli Lilly and Company’s logo is displayed during a press conference in Houston, Texas, U.S., Sept. 23, 2025.…
New study identifies key pathway for delivering antisense cancer drugs
Antisense oligonucleotides (ASOs) have been proposed as a therapeutic approach to shut down the production of faulty proteins…
Foundayo: Eli Lilly wins U.K. approval, challenging Wegovy weight-loss pill
Eli Lilly has won its first approval to sell its weight-loss drug Foundayo outside the U.S., allowing it…
Eli Lilly, Novo Nordisk earnings show widening divide in GLP-1 market
The Eli Lilly and Novo Nordisk logos. Mike Blake | Tom Little | Reuters The diverging paths of…
Eli Lilly (LLY) earnings Q2 2026
Eli Lilly on Wednesday reported second-quarter earnings and revenue that blew past estimates and hiked its full-year sales outlook,…
Eli Lilly to offer retatrutide access given earlier to just one patient
Lizzy leads STAT’s coverage of the FDA. Her stories explore the relationship between politics and science at the…
Novo Nordisk shares fall after heart medicine trial results
Shares of Novo Nordisk fell as much as 10% on Friday after the drugmaker said a late-stage heart…